The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Yangambin     4,8-bis(3,4,5- trimethoxyphenyl)-3,7...

Synonyms: Epiyangambin, NSC-83441, KST-1B8896, NSC-172767, MEGxp0_000712, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC83441

  • We also evidenced that the hemoconcentration, thrombocytopenia, and leucocytosis noted after i.v. PAF were all attenuated by yangambin [1].
  • The protective effects of a new, selective, plant-derived platelet-activating factor (PAF) antagonist, yangambin, on the cardiovascular alterations and mortality due to endotoxic shock were investigated in anaesthetized rats [2].
  • In addition, yangambin also suppressed the pleural neutrophil infiltration triggered by LTB4 as well as the blood thrombocytopenia and intestinal anaphylaxis elicited by antigen in rats [1].

Psychiatry related information on NSC83441


High impact information on NSC83441


Chemical compound and disease context of NSC83441


Biological context of NSC83441

  • Moreover, yangambin at 10(-5) M did not inhibit the platelet aggregation induced by ADP (5 x 10(-7) M), collagen (0.1 microgram ml-1), or thrombin (0.05 U ml-1) [6].
  • Both unlabelled PAF and yangambin competitively displaced [3H]-PAF binding with an IC50 of 1.54 +/- 0.37 nM and 1.93 +/- 0.53 microM, respectively [6].
  • The incubation of rabbit blood neutrophils with yangambin at 10(-5) M did not prevent PAF-induced in vitro chemotaxis in conditions where the PAF antagonist SR 27417 at 10(-5) M abolished the phenomenon [6].
  • Yangambin, a new naturally-occurring platelet activating receptor (PAF) receptor antagonist competitively displaced [3H]-PAF from its high affinity binding sites on washed human platelets with a Ki value of 1.1 +/- 0.3 microM (n = 3) [7].

Anatomical context of NSC83441


Gene context of NSC83441


Analytical, diagnostic and therapeutic context of NSC83441


  1. Anti-allergic properties of the natural PAF antagonist yangambin. Serra, M.F., Diaz, B.L., Barreto, E.O., Pereira, A.P., Lima, M.C., Barbosa-Filho, J.M., Cordeiro, R.S., Martins, M.A., de Silva, P.M. Planta Med. (1997) [Pubmed]
  2. Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock. Araújo, C.V., Barbosa-Filho, J.M., Cordeiro, R.S., Tibiriçá, E. Naunyn Schmiedebergs Arch. Pharmacol. (2001) [Pubmed]
  3. Central nervous system activity of yangambin from Ocotea duckei Vattimo (Lauraceae) in mice. de Sousa, F.C., Pereira, B.A., Lima, V.T., Lacerda, C.D., Melo, C.T., Barbosa-Filho, J.M., Vasconcelos, S.M., Viana, G.S. Phytotherapy research : PTR. (2005) [Pubmed]
  4. Yangambin, a lignan obtained from Ocotea duckei, differentiates putative PAF receptor subtypes in the gastrointestinal tract of rats. Jesus-Morais, C.M., Assis, E.F., Cordeiro, R.S., Barbosa-Filho, J.M., Lima, W.T., Silva, Z.L., Bozza, P.T., Castro-Faria-Neto, H.C. Planta Med. (2000) [Pubmed]
  5. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. Castro-Faria-Neto, H.C., Martins, M.A., Silva, P.M., Bozza, P.T., Cruz, H.N., de Queiroz-Paulo, M., Kaplan, M.A., Cordeiro, R.S. Journal of lipid mediators. (1993) [Pubmed]
  6. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies. Castro-Faria-Neto, H.C., Bozza, P.T., Cruz, H.N., Silva, C.L., Violante, F.A., Barbosa-Filho, J.M., Thomas, G., Martins, M.A., Tibiriçá, E.V., Noel, F. Planta Med. (1995) [Pubmed]
  7. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin. Herbert, J.M., Castro-Faria-Neto, H.C., Barbosa-Filho, J.M., Cordeiro, R.S., Tibiriça, E. Journal of lipid mediators and cell signalling. (1997) [Pubmed]
  8. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies. Castro-Faria-Neto, H.C., Araújo, C.V., Moreira, S., Bozza, P.T., Thomas, G., Barbosa-Filho, J.M., Cordeiro, R.S., Tibiriçá, E.V. Planta Med. (1995) [Pubmed]
WikiGenes - Universities